Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review
Abstract Objective Bupropion, an antidepressant inhibiting the reuptake of dopamine and noradrenaline, should be useful to treat depressive symptoms in patients with Parkinson’s disease (PD). Limited and conflicting literature data questioned its effectiveness and safety in depressed PD patients and...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-05-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-022-02668-4 |
| _version_ | 1828344436397965312 |
|---|---|
| author | Matteo Vismara Beatrice Benatti Gregorio Nicolini Ilaria Cova Edoardo Monfrini Alessio Di Fonzo Vincenza Fetoni Caterina A. Viganò Alberto Priori Bernardo Dell’Osso |
| author_facet | Matteo Vismara Beatrice Benatti Gregorio Nicolini Ilaria Cova Edoardo Monfrini Alessio Di Fonzo Vincenza Fetoni Caterina A. Viganò Alberto Priori Bernardo Dell’Osso |
| author_sort | Matteo Vismara |
| collection | DOAJ |
| description | Abstract Objective Bupropion, an antidepressant inhibiting the reuptake of dopamine and noradrenaline, should be useful to treat depressive symptoms in patients with Parkinson’s disease (PD). Limited and conflicting literature data questioned its effectiveness and safety in depressed PD patients and extended its use to other neuropsychiatric symptoms associated with this disorder. Design The databases PubMed, Embase, Web of Sciences, Cochrane Library, and the grey literature were searched. Following a scoping review methodology, articles focusing on Bupropion uses in PD patients who manifested depressive or other neuropsychiatric alterations were reviewed. Results Twenty-three articles were selected, including 7 original articles, 3 systematic reviews or meta-analyses, 11 case reports, 1 clinical guideline, and 1 expert opinion. Bupropion showed considerable effectiveness in reducing depressive symptoms, particularly in relation to apathy. Solitary findings showed a restorative effect on compulsive behaviour secondary to treatment with dopamine as well as on anxiety symptoms. The effect on motor symptoms remains controversial. The safety profile of this medication seems positive, but additional precautions should be used in subjects with psychotic symptoms. Conclusion The available literature lacks good evidence to support the use of Bupropion in PD patients presenting depressive symptoms. Further investigations are needed to extend and confirm reported findings and to produce accurate clinical guidelines. |
| first_indexed | 2024-04-13T23:57:15Z |
| format | Article |
| id | doaj.art-291c8c4da0424bbca6bcb3e4d0fc843a |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-04-13T23:57:15Z |
| publishDate | 2022-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-291c8c4da0424bbca6bcb3e4d0fc843a2022-12-22T02:23:51ZengBMCBMC Neurology1471-23772022-05-0122112010.1186/s12883-022-02668-4Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping reviewMatteo Vismara0Beatrice Benatti1Gregorio Nicolini2Ilaria Cova3Edoardo Monfrini4Alessio Di Fonzo5Vincenza Fetoni6Caterina A. Viganò7Alberto Priori8Bernardo Dell’Osso9Department of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of MilanDepartment of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of MilanDepartment of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of MilanNeurology Unit, Luigi Sacco University HospitalDino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of MilanFoundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neurology UnitNeurology Department, ASST Fatebenefratelli SaccoDepartment of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan“Aldo Ravelli” Center for Neurotechnology and Brain Therapeutic, University of MilanDepartment of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of MilanAbstract Objective Bupropion, an antidepressant inhibiting the reuptake of dopamine and noradrenaline, should be useful to treat depressive symptoms in patients with Parkinson’s disease (PD). Limited and conflicting literature data questioned its effectiveness and safety in depressed PD patients and extended its use to other neuropsychiatric symptoms associated with this disorder. Design The databases PubMed, Embase, Web of Sciences, Cochrane Library, and the grey literature were searched. Following a scoping review methodology, articles focusing on Bupropion uses in PD patients who manifested depressive or other neuropsychiatric alterations were reviewed. Results Twenty-three articles were selected, including 7 original articles, 3 systematic reviews or meta-analyses, 11 case reports, 1 clinical guideline, and 1 expert opinion. Bupropion showed considerable effectiveness in reducing depressive symptoms, particularly in relation to apathy. Solitary findings showed a restorative effect on compulsive behaviour secondary to treatment with dopamine as well as on anxiety symptoms. The effect on motor symptoms remains controversial. The safety profile of this medication seems positive, but additional precautions should be used in subjects with psychotic symptoms. Conclusion The available literature lacks good evidence to support the use of Bupropion in PD patients presenting depressive symptoms. Further investigations are needed to extend and confirm reported findings and to produce accurate clinical guidelines.https://doi.org/10.1186/s12883-022-02668-4BupropionParkinson’s diseaseDepressionNeuropsychiatric symptomsPharmacological treatment |
| spellingShingle | Matteo Vismara Beatrice Benatti Gregorio Nicolini Ilaria Cova Edoardo Monfrini Alessio Di Fonzo Vincenza Fetoni Caterina A. Viganò Alberto Priori Bernardo Dell’Osso Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review BMC Neurology Bupropion Parkinson’s disease Depression Neuropsychiatric symptoms Pharmacological treatment |
| title | Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review |
| title_full | Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review |
| title_fullStr | Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review |
| title_full_unstemmed | Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review |
| title_short | Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review |
| title_sort | clinical uses of bupropion in patients with parkinson s disease and comorbid depressive or neuropsychiatric symptoms a scoping review |
| topic | Bupropion Parkinson’s disease Depression Neuropsychiatric symptoms Pharmacological treatment |
| url | https://doi.org/10.1186/s12883-022-02668-4 |
| work_keys_str_mv | AT matteovismara clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT beatricebenatti clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT gregorionicolini clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT ilariacova clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT edoardomonfrini clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT alessiodifonzo clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT vincenzafetoni clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT caterinaavigano clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT albertopriori clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview AT bernardodellosso clinicalusesofbupropioninpatientswithparkinsonsdiseaseandcomorbiddepressiveorneuropsychiatricsymptomsascopingreview |